Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Not sure I wanted to bring this topic up (again.)

<< Previous

Bullboard Posts

Next >>

Comment by 2b7f6fabon Jun 13, 2024 11:55am

132 Views

Post# 36087234

RE:RE:RE:Not sure I wanted to bring this topic up (again.)

At this stage I think it would take $2 billion, if after succesful ph1 gbm/nsclc then $6 to $10 billion.
Let's consider Merck's keytruda patents fall off in a few years, maybe they can get it extended. Merck's market cap is $326 billion. Keytruda accounts for 1/3 of sales and probably more than half it's market cap. $2 billion today is not much to protect their revenue stream and probably enhance it considerably. Conversely, lots of other big pharma watching. I would love to see a friendly or hostile bid @ $1.5 this coming week. It would end up being much more before it's done, imo.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023